TEVA(TEVA) The Motley Fool·2025-01-29 19:26Stock Performance - Shares of Teva Pharmaceutical Industries lost 13.5% as of 1:15 p.m. ET, underperforming the S&P 500 and Nasdaq Composite, which lost 0.5% and 0.9%, respectively [1] Financial Results - Teva reported Q4 sales of $4.2 billion and fiscal year 2024 sales of $16.5 billion, up from 2023's revenue of $15.9 billion, slightly exceeding expectations [2] - Q4 EPS was $0.71, down significantly from Q4 2023's $1.00 but slightly exceeding the expected $0.70 [2] Guidance and Investor Sentiment - The company's 2025 EPS forecast disappointed investors, with the high end of the range ($2.65) coming in below the expected $2.76 [3] Strategic Initiatives - Teva is implementing its "Pivot to Growth strategy," focusing on cost reduction through reorganization, generics, and R&D pipeline success, though the latter has no guarantees or clear timeline [4] - The company has key drugs in later stages of trials, including treatments for ulcerative colitis and Crohn's disease, which show promise but require significant effort [5]